Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…A novel single-cell reporter identifies regulators of the endogenous PINK1-Parkin mitochondrial quality control pathway
Objective: We aimed to identify genome-wide regulators of the PINK1-Parkin pathway using a novel flow cytometry reporter, endogenously tagged MFN2, as a readout of the…LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson’s disease
Objective: We focus on the novel endogenous neural repair function that comes from the mitochondrial transfer, and we aim to elucidate the molecular mechanism by…Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging
Objective: To determine age-associated changes in the size, density, movement, and dynamics of mitochondria as a function of sex, using microRNA-induced neurons derived from primary…Alpha-Synuclein and Mitochondria Quality Control in Parkinson’s Disease: A Literature Review
Objective: To provide an overview of the current knowledge on alpha-synuclein (αS) interactions with mitochondrial quality control (MQC) pathways in Parkinson’s disease (PD). Background: The…Utility of Whole Exome Sequencing in movement disorders potentially related to Mitochondrial cytopathies
Objective: To describe the clinic-genetic profile of clinically suspected mitochondrial cytopathies with movement disorders (MDs). Background: Literature on the clinico-genetic spectrum of movement disorders related…A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson’s disease
Objective: To understand the molecular function of a novel missense PINK1 variant identified in an Indian family with Parkinson’s disease (PD). Background: The molecular understanding…Patterns of Parkinson disease mitochondrial brain function indexed by 31P magnetic resonance spectroscopy
Objective: To examine whether individuals with PD show greater temporal than frontal high energy phosphate metabolism (31P MRS ATP) that is similar or different from…Exploring mitochondrial mechanisms defining Parkinson’s disease penetrance in LRRK2 G2019S neuronal cultures
Objective: We explored mitochondria as integrators of genetics and environment in LRRK2 G2019S neuronal models. Specifically, we aimed to unravel mitochondrial mechanisms that define the…Multidimensional phenotyping of human stem cell-derived midbrain dopaminergic neurons from a SNCA triplication carrier for drug screening applications
Objective: We hypothesized that combining multiple Parkinson's disease (PD) relevant cellular phenotypes will increase the accuracy, stability, and usability of human midbrain dopaminergic (mDA) neuronal…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »